• Explore /
  • Poster
  • / Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).

Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).

Abstract Poster

Authors

null

Katharine Andress Rowe Price

Department of Oncology, Mayo Clinic, Rochester, MN

Katharine Andress Rowe Price , John M. Kaczmar , Francis P. Worden , Lauren V Wood , David T. Schaaf , Nathalie Riebel , Marya F. Chaney , Jared Weiss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04260126

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6012)

DOI

10.1200/JCO.2023.41.16_suppl.6012

Abstract #

6012

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Karim Amrane Sr.

First Author: Talal El Zarif

First Author: Susanna Varkey Ulahannan

First Author: Daniel Olson